Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell.
## Primary Indications
* Short-term treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-induced upper GI bleeding (ICU settings).
## Adult Dosing
* **GERD (Erosive Esophagitis):** 40 mg orally or IV once daily for up to 8 weeks. Maintenance therapy: 40 mg daily.
* **Hypersecretory Disorders:** 40 mg twice daily. Doses up to 240 mg/day have been utilized; titration based on patient need is required.
* **Stress Ulcer Prophylaxis:** 40 mg IV daily.
## Pediatric Dosing
* **GERD (≥5 years):**
* 15 kg to <40 kg: 20 mg once daily.
* ≥40 kg: 40 mg once daily.
* **Safety/Efficacy:** Not established for children <5 years of age.
## Dose Adjustments
* **Hepatic Impairment:** Reduce frequency in severe hepatic impairment (Child-Pugh C). Maximum dose may be limited; monitor clinical response.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, and increased risk of bone fractures.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole, iron salts).
* **Methotrexate:** May increase serum levels of methotrexate, particularly in high-dose therapy.
* **Warfarin:** Increased INR/prothrombin time has been reported; monitor closely.
* **Clopidogrel:** Potential reduced antiplatelet effect, though clinical significance remains debated.
## Monitoring
* Monitor for signs/symptoms of CDAD (diarrhea that does not improve).
* Baseline and periodic serum magnesium (if long-term use >1 year).
* For long-term use, evaluate for B12 deficiency.
## Clinical Pearls
* Administer oral delayed-release tablets intact; do not crush or chew.
* Oral administration is preferred; IV usage should be reserved for patients unable to take oral medication and transitioned to oral as soon as possible.
* PPIs are intended for the shortest duration necessary; consider periodic reassessment for deprescribing to avoid long-term risks (e.g., osteoporosis, enteric infections).
* Dosing specifics may vary based on institutional protocols or specific formulation (e.g., IV reconstitution requirements).
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Always verify current prescribing information, institutional guidelines, and drug compatibility data via reliable primary sources before administering medication.
